Special Issues
TSKgel UP-SW3000 columns are 2 µm SEC columns designed for the analysis of monoclonal antibodies and other biopharma products. Higher resolution can be achieved for the separation of antibody monomers, dimers, and higher order aggregates with a TSKgel UP-SW3000 column compared to a competitor UHPLC column. The TSKgel UP-SW3000 column provided excellent reproducibility for the peak parameters of retention time, asymmetry, and column efficiency. As demonstrated by the %RSD values, injection-to-injection reproducibility was superior to the competitor column.
TSKgel UP-SW3000 columns are 2 µm SEC columns designed for the analysis of monoclonal antibodies and other biopharma products and can be used on both HPLC and UHPLC systems. The columns are packed with silica-based beads shielded with a hydrophilic diol-type bonded phase that prevents the silica surface from interacting with protein samples.
TSKgel UP-SW3000 columns are available in 4.6 mm ID with 15 or 30 cm length. Higher resolution can be achieved for the separation of antibody monomers, dimers, and higher order aggregates with a TSKgel UP-SW3000 column compared to a competitor UHPLC column. In addition, a TSKgel UP-SW3000 column yielded very low percent relative standard deviation (%RSD) for peak parameters including: retention times, peak asymmetry, and efficiency, demonstrating the exceptional reproducibility of this column versus a competitor UHPLC column.
Click here to view full-size graphic
The separation of a QC standard protein mixture on a 15 cm TSKgel UP-SW3000 column compared to a competitor UHPLC column of the same length is depicted in Figures 1a and 1b. Clearly, the TSKgel UP-SW3000 column yielded better separation of thyroglobulin on the high molecular weight (HMW) side of the monoclonal antibody monomer of 150 kDa, as indicated by the brackets in Figure 1b. In addition, the resolution between thyroglobulin and γ-globulin peaks and the γ-globulin and ovalbumin peaks also have higher resolution in the case of the TSKgel UP-SW3000 column although particle size is slightly larger than in the competitor column.
Figure 1a: Comparison of QC standard protein mixture using TSKgel UP-SW3000 and competitor column.
Figure 1b: Comparison of QC standard protein mixture using TSKgel UP-SW3000 and competitor column – zoomed in view.
The number of theoretical plates for the competitor column was 22,618, while 27,082 was obtained for the TSKgel UP-SW3000 column. In the case of γ-globulin (150 kDa), the TSKgel UP-SW3000 column also yielded a larger number of theoretical plates (2,738) compared to 2,675 for the competitor column. The difference in intensity of the proteins comes from two different preparations containing the same amount of pAba.
Figure 2a: mAb analysis using TSKgel UP-SW3000 column.
Figure 2b: mAb analysis using competitor UHPLC column.
A monoclonal antibody was analyzed using a TSKgel UP-SW3000, 30 cm column and a 30 cm competitor UHPLC column, as shown in Figures 2a and 2b. The TSKgel UP-SW3000 column provided excellent reproducibility for the peak parameters of retention time, asymmetry, and column efficiency. Injection-to-injection reproducibility was superior to the competitor column as demonstrated by the %RSD values in Table I.
Table I: Comparative analysis of peak parameters of TSKgel UP-SW3000 and competitor column.
TSKgel UP-SW3000 columns are 2 µm SEC columns designed for the analysis of monoclonal antibodies and other biopharma products. Higher resolution can be achieved for the separation of antibody monomers, dimers, and higher order aggregates with a TSKgel UP-SW3000 column compared to a competitor UHPLC column. The TSKgel UP-SW3000 column provided excellent reproducibility for the peak parameters of retention time, asymmetry, and column efficiency. As demonstrated by the %RSD values, injection-to-injection reproducibility was superior to the competitor column.
Tosoh Bioscience and TSKgel are registered trademarks of Tosoh Corporation.
Tosoh Bioscience LLC
3604 Horizon Drive, Suite 100, King of Prussia, PA 19406
tel. (484) 805-1219, fax (610) 272-3028
Website: www.tosohbioscience.com
Free Poster: NDSRI Risk Assessment and Trace-Level Analysis of N-Nitrosamines
April 25th 2025With increasing concern over genotoxic nitrosamine contaminants, regulatory bodies like the FDA and EMA have introduced strict guidelines following several high-profile drug recalls. This poster showcases a case study where LGC and Waters developed a UPLC/MS/MS method for quantifying trace levels of N-nitroso-sertraline in sertraline using Waters mass spectrometry and LGC reference standards.
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
Using the Carcinogenic Potency Categorisation Approach (CPCA) to Classify N-nitrosamine Impurities
April 25th 2025Learn how to manage nitrosamine impurities in pharmaceuticals with our free infographic. Discover how the CPCA approach establishes acceptable intake limits and guides the selection of NDSRI reference samples. Stay compliant and ensure safety with our ISO-accredited standards.